Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 299-305

  Hasanovic, Adnan ^a   Ang, Daphne ^a   Moreira, Andre L ^a   Zakowski, Maureen F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Cytology; Diagnosis; EGFR mutation; Immunohistochemistry

Indexed keywords

CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; BONE BIOPSY; CANCER THERAPY; CYTOLOGY; DNA DEGRADATION; DNA DETERMINATION; EXON; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; VALIDATION STUDY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BIOPSY; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84863781238     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.004     Document Type: Article

References (38)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
6. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
7. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
8. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
9. D'Angelo S.P., Pietanza M.C., Johnson M.L., Riely G.J., Miller V.A., Sima C.S., et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011, 29:2066-2070.
10. Girard N., Sima C.S., Jackman D.M., Sequist L.V., Chen H., Yang J.C., et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012, 39:366-372.
11. Reinersman J.M., Johnson M.L., Riely G.J., Chitale D.A., Nicastri A.D., Soff G.A., et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011, 6:28-31.
12. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
13. D'Angelo S.P., Park B., Azzoli C.G., Kris M.G., Rusch V., Ladanyi M., et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg 2011, 141:476-480.
14. Pan Q., Pao W., Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005, 7:396-403.
15. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29:2121-2127.
16. Rekhtman N., Brandt S.M., Sigel C.S., Friedlander M.A., Riely G.J., Travis W.D., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6:451-458.
17. Talaulikar D., Gray J.X., Shadbolt B., McNiven M., Dahlstrom J.E. A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. J Clin Pathol 2008, 61:119-123.
18. Wickham C.L., Sarsfield P., Joyner M.V., Jones D.B., Ellard S., Wilkins B. Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products. Mol Pathol 2000, 53:336.
19. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.
20. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12:169-176.
21. Ilie M.I., Hofman V., Bonnetaud C., Havet K., Lespinet-Fabre V., Coelle C., et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010, 457:483-495.
22. Kato Y., Peled N., Wynes M.W., Yoshida K., Pardo M., Mascaux C., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5:1551-1558.
23. Kawahara A., Azuma K., Sumi A., Taira T., Nakashima K., Aikawa E., et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: Rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011, 74:35-40.
24. Kawahara A., Yamamoto C., Nakashima K., Azuma K., Hattori S., Kashihara M., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16:3163-3170.
25. Kitamura A., Hosoda W., Sasaki E., Mitsudomi T., Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010, 16:3349-3355.
26. Kozu Y., Tsuta K., Kohno T., Sekine I., Yoshida A., Watanabe S., et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011, 73:45-50.
27. Nakamura H., Mochizuki A., Shinmyo T., Ando K., Kurimoto N., Yokote K., et al. Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res 2010, 30:5233-5237.
28. Simonetti S., Molina M.A., Queralt C., de Aguirre I., Mayo C., Bertran-Alamillo J., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 8:135.
29. World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura thymus and heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
30. Li A.R., Chitale D., Riely G.J., Pao W., Miller V.A., Zakowski M.F., et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008, 10:242-248.
31. Sequist L.V., Joshi V.A., Janne P.A., Bell D.W., Fidias P., Lindeman N.I., et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006, 12:4403s-4408s.
32. de Lima Lopes G., Segel J.E., Tan D.S., Do Y.K., Mok T., Finkelstein E.A. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2012, 118:1032-1039.
33. da Cunha Santos G., Saieg M.A., Geddie W., Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011, 119:80-91.
34. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009, 117:67-72.
35. Rekhtman N., Ang D.C., Sima C.S., Travis W.D., Moreira A.L. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011, 24:1348-1359.
36. Travis W.D., Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32:22-31.
37. Azuma K., Okamoto I., Kawahara A., Taira T., Nakashima K., Hattori S., et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 2012, 7:122-127.
38. Wu S.G., Chang Y.L., Lin J.W., Wu C.T., Chen H.Y., Tsai M.F., et al. Including total EGFR staining in scoring improves EGFR mutations detected by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011, 6(8):e23303. doi:10.1371.